Most Read Articles
3 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 5 days ago

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Medication nonadherence may lead to treatment escalation in children with UC

03 Nov 2019

In paediatric patients with ulcerative colitis (UC), nonadherence to mesalazine negatively affects its therapeutic efficacy and may, in turn, result in treatment escalation, according to data from PROTECT.

PROTECT included 268 newly diagnosed paediatric UC patients (mean age, 12.3 years; 50 percent female). All patients received standardized mesalazine, with pre‐established criteria for escalation to thiopurines or anti‐tumour necrosis factor alpha (TNFα inhibitors). Adherence was monitored using pill bottles with electronic caps.

Researchers examined whether longitudinal adherence to treatment was associated with steroid‐free remission at week 52 (defined as quiescent disease on mesalazine alone with no corticosteroids ≥4 weeks prior) and need for treatment escalation (defined as introduction of immunomodulators, calcineurin‐inhibitors or anti‐TNFα inhibitors).

Results revealed that average mesalazine adherence trajectories were not predictive of steroid‐free remission at week 52. On the other hand, declining adherence over time (adherence rate of ≤85.7 percent at month 6) showed a strong association with treatment escalation (p=0.001).

According to the researchers, the present data highlight the importance of targeting adherence difficulties early in the disease course to reduce the likelihood of the need for treatment escalation in this population. They also stressed that treatment escalation is not based on suboptimal adherence to maintenance medication, but rather on disease response (or lack of response) to maintenance medication.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 5 days ago

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.